End Stage Renal Disease (ESRD) Drug Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Size, Share & Trends, Drivers, Restraints, Opportunities, Manufacturer, Applications, And Segments

  • AMR-1063125
  • May 2021
  • Pharmaceuticals
  • 133 Pages
The End Stage Renal Disease (ESRD) Drug Market research report comprises of an overall in depth-analysis such as market drivers, opportunities, restraints, latest developments and trends, segmentation of the market, competitive analysis, global as well as regional analysis by showcasing how each of these factors can improve the further growth of the market on an overall perspective. The report also showcases the overall market value which includes the historic data (2018-2019) and forecast data (2020-2028) generated through the revenue (USD Mn)
 
Report Parameters Details of Parameter
Market Size xx Million
Based Year 2020
Forecast Period Covered 2020 – 2028
Units for value Revenue in USD million and CAGR from 2020 to 2028
Covered Segments Component, Types, Applications, End-Users, and more.
Companies Covered AbbVie Inc., Amgen, AstraZeneca, Sanofi, Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bayer AG, Vifor Pharma Management Ltd., Akebia Drugs, Inc.
Region Covered North America, Europe, Asia Pacific, Latin America, Middle East and Africa

COVID-19 Coverage
With the beginning of the COVID-19 pandemic in early 2020, all major economies around the world enforced severe lockdown restrictions to curb the spread of the virus. Apart from a few sectors such as healthcare and related essential services, most of the industries suffered tremendously due to inability to function in a normal fashion. Moreover, even some of the essential sectors suffered due to delays caused by supply chain disruptions and other travel complexities. However, with massive vaccination drives in most of the developed economies, some of the economies across the world experienced economic recovery from 2021. The End Stage Renal Disease (ESRD) Drug market is expected to gain momentum in such economies and probably recover some of the losses inflicted in the year 2020. With continued efforts towards curbing the virus in the developing economies, the End Stage Renal Disease (ESRD) Drug market is expected to attain Pre COVID-19 levels by mid-2022.

End Stage Renal Disease (ESRD) Drug Report’s Assessment
The research report is formulated such that it offers a deep understating on the market drivers that are assimilating the growth of the market, the market opportunities that are going to provide future growth factors for the market and the market restraints which showcase the reasons as to why the market can get hampered and dissimilated. All these factors are considered keeping in view the historic and forecast analysis which can enlighten the above mentioned factors.

Thereby at a glance a reader can understand all the factors and prospects of the End Stage Renal Disease (ESRD) Drug market and how it can assimilate and dissimilate based on each of the factors and figures mentioned in the report

End Stage Renal Disease (ESRD) Drug Market Competitive and Premeditated Analysis
In the End Stage Renal Disease (ESRD) Drug report major factors such latest tactical developments, competitors, research and development, participation of each region in the market and the competition among them, the latest news regarding company acquisitions and product launch, revenue of the competitors as well as the key offerings they provide all these factors are mentioned in the report with reasons to justify and understand them in depth.

The readers and purchaser of the End Stage Renal Disease (ESRD) Drug research report can gain a comprehensive understanding of the market competition, the revenue of each major players and their contribution towards the market, attractive proposition analysis is provided in the report which sub divides the segments with respect to the largest segment that has contributed to the market growth and the fastest growing segment based on the size of the market as well as its overall appeal.
 
Major Key Players for Global End Stage Renal Disease (ESRD) Drug Market:
The End Stage Renal Disease (ESRD) Drug market research report offers the company profile of major key players including progress trends, competitive landscape breakdown, and key in regions development status. AbbVie Inc., Amgen, AstraZeneca, Sanofi, Kyowa Kirin Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bayer AG, Vifor Pharma Management Ltd., Akebia Drugs, Inc.

The End Stage Renal Disease (ESRD) Drug market report showcases vast potentials of growth and assimilation which is going to provide the industry numerous opportunities to grow and generate revenue by understanding the segments and which segment is a potential part to increase the disposable income in the present and upcoming years.

End Stage Renal Disease (ESRD) Drug Market Segmentation Analysis:
Each of the segment is explained in brief along with the revenue it generates for the market based on the historic and forecast data by highlighting the largest segment and the fastest growing segment with reasons to justify it.

The Global segmentation of the End Stage Renal Disease (ESRD) Drug market:
By Product Type
Calcimimetics
Vitamin D
Sterols
Potassium Binders
Calcium-Based Phosphate Binders
Others
Indication
End Stage Renal Disease
ESRD Induced Hyperparathyroidism
End Stage Renal Disease
ESRDInduced Hyperphosphatemia
End Stage Renal Disease
ESRD Induced Hyperkalaemia
Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies


Regional Analysis of the End Stage Renal Disease (ESRD) Drug market:
The End Stage Renal Disease (ESRD) Drug market is dived based on different regions such as North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. And the analysis of each region is provided by highlighting the largest contribution region, the fastest growing region and the factors that is keeping the market active in the other regions is also mentioned in depth. Each regional segment also comprises of the revenue each segment holds in a specific region with reasons to justify the values.

By Regions:
  • North America (U.S and Canada)
  • Europe (U.K., Germany and France)
  • Asia Pacific (China, India and Japan)
  • Latin America (Mexico and Brazil)
  • Middle East and Africa (GCC Countries and South Africa)
 


Major Factors Included and highlighted in the End Stage Renal Disease (ESRD) Drug report are as follows:
  • The overall market value along with historic and future data analysis.
  • The Growth drivers, opportunities and restraints are mention in detail.
  • The size of the entire End Stage Renal Disease (ESRD) Drug market on a global perspective.
  • The CAGR value of the overall market from 2020 to 2028.
  • COVID-19 impact on the End Stage Renal Disease (ESRD) Drug market and how it is coping up with the situation.
  • Major competitors and their contribution towards the market.
  • The segmentation analysis is included which provides a clear picture of the market bifurcation.
  • Tables and graphs that can easily been understood at a glance
  • Latest trends and news related to the End Stage Renal Disease (ESRD) Drug market is included in the report.
Key Analytical Areas:
The report aims to offer a complete solution to various businesses operating in the End Stage Renal Disease (ESRD) Drug market in making strategic decisions based on credible information and actionable insights. Thereby, the report covers various aspects of your requirements such as industry overview, market dynamics, regional analysis and competitive landscape. The report aims to provide insights to businesses in the End Stage Renal Disease (ESRD) Drug market for numerous purposes such as:

     1. Strategic Decision Making:
With the help of this report, key decision makers can quickly analyze and identify growth opportunities in terms of numerous segments across various geographical regions. Thereby, this report enables organizations to identify and make strategic investments in specific market segments in order to gain maximum return on investment.

     2. Actionable Insights:
The report offers a deep dive into how companies are leveraging market conditions to make the most in the End Stage Renal Disease (ESRD) Drug market. Thereby, the report offers numerous actionable insights into the best practices and key success factors relevant in the End Stage Renal Disease (ESRD) Drug market. Using the insights included in the report, businesses can make quick decisions to achieve success in business operations.

     3. Competitive Snapshot:
In addition, to detailed information on the companies operating in the End Stage Renal Disease (ESRD) Drug market, the report also includes a competitive snapshot of all the companies covered in the report. Thereby, this offers a visual representation of how all the companies stand comparatively based on their competencies, geographic presence, market hold, years of operations, employee and financial strength, among others.

Manufacturers and Segments

  • AbbVie Inc.
  • Amgen
  • AstraZeneca
  • Sanofi
  • Kyowa Kirin Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma Inc.
  • Bayer AG
  • Vifor Pharma Management Ltd.
  • Akebia Drugs, Inc.
  • Calcimimetics
  • Vitamin D
  • Sterols
  • Potassium Binders
  • Calcium-Based Phosphate Binders
  • Others
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

Have query on this report?

Make an Enquiry
1. Preface
     1.1. Report Scope and Description
     1.2. Research Methodology
          1.2.1. Phase I-Secondary Research
          1.2.2. Phase II-Primary Research
          1.2.3. Phase II-Expert Panel Review
          1.2.4. Assumptions
          1.2.5. Approach Adopted

2. Executive Summarysegment Form
     2.1. Global End Stage Renal Disease (ESRD) Drug Market Snapshot
          2.1.1. Global End Stage Renal Disease (ESRD) Drug Market By Product Type,2019
               2.1.1.1.Calcimimetics
               2.1.1.2.Vitamin D
               2.1.1.3.Sterols
               2.1.1.4.Potassium Binders
               2.1.1.5.Calcium-Based Phosphate Binders
               2.1.1.6.Others
          2.1.2. Global End Stage Renal Disease (ESRD) Drug Market By Distribution Channel,2019
               2.1.2.1.Hospital Pharmacies
               2.1.2.2.Online Pharmacies
               2.1.2.3.Retail Pharmacies
          2.1.3. Global End Stage Renal Disease (ESRD) Drug Market By End-use,2019
          2.1.4. Global End Stage Renal Disease (ESRD) Drug Market By Geography,2019

3. Global End Stage Renal Disease (ESRD) Drug Market Dynamics
     3.1. Market Overview
     3.2. Market Inclination Insights Analysis
     3.3. Drivers
     3.4. Challenges
     3.5. Future Prospects
     3.6. Impact Analysis of Drivers and Challenges During the Forecast Period, (2020-2028)

4. Global End Stage Renal Disease (ESRD) Drug Market Size (US$), By Product Type, 2018 – 2028 
     4.1. Overview
          4.1.1. Market Share Analysis By Product Type, 2019 vs.2028
          4.1.2. Attractive Investment Proposition By Product Type, 2020
     4.2. Global End Stage Renal Disease (ESRD) Drug Market Size (US$), By Product Type, 2018 – 2028

5. Global End Stage Renal Disease (ESRD) Drug Market Size (US$), By Distribution Channel, 2018 – 2028 
     5.1. Overview
          5.1.1. Market Share Analysis By Distribution Channel, 2019 vs.2028
          5.1.2. Attractive Investment Proposition By Distribution Channel, 2020
     5.2. Global End Stage Renal Disease (ESRD) Drug Market Size (US$), By Distribution Channel, 2018 – 2028

6. Global End Stage Renal Disease (ESRD) Drug Market Size (US$), By End-use, 2018 – 2028 
     6.1. Overview
          6.1.1. Market Share Analysis By End-use, 2019 vs.2028
          6.1.2. Attractive Investment Proposition By End-use, 2020
     6.2. Global End Stage Renal Disease (ESRD) Drug Market Size (US$), By End-use, 2018 – 2028

7. Global End Stage Renal Disease (ESRD) Drug Market Size (US$), By Geography, 2018 – 2028
     7.1. Overview
          7.1.1. Market Share Analysis by Geography, 2019 vs. 2028
          7.1.2. Attractive Investment Proposition by Geography, 2020
     7.2. North America End Stage Renal Disease (ESRD) Drug Market Analysis, 2018 – 2028 
          7.2.1. North America End Stage Renal Disease (ESRD) Drug Market Size (US$), By Country, 2018 – 2028 
               7.2.1.1. U.S.
               7.2.1.2. Canada
          7.2.2. North America End Stage Renal Disease (ESRD) Drug Market Size (US$), By Product Type, 2018 – 2028
          7.2.3. North America End Stage Renal Disease (ESRD) Drug Market Size (US$), By Distribution Channel, 2018 – 2028
          7.2.4. North America End Stage Renal Disease (ESRD) Drug Market Size (US$), By End-use, 2018 – 2028
     7.3. Europe End Stage Renal Disease (ESRD) Drug Market Analysis, 2018 – 2028 
          7.3.1.  Europe End Stage Renal Disease (ESRD) Drug Market Size (US$), By Country, 2018 – 2028 
               7.3.1.1. U.K.
               7.3.1.2. Germany
               7.3.1.3. France
               7.3.1.4. Rest of Europe
          7.3.2. Europe End Stage Renal Disease (ESRD) Drug Market Size (US$), By Product Type, 2018 – 2028
          7.3.3. Europe End Stage Renal Disease (ESRD) Drug Market Size (US$), By Distribution Channel, 2018 – 2028
          7.3.4. Europe End Stage Renal Disease (ESRD) Drug Market Size (US$), By End-use, 2018 – 2028
     7.4. Asia Pacific End Stage Renal Disease (ESRD) Drug Market Analysis , 2018 – 2028
          7.4.1.  Asia Pacific End Stage Renal Disease (ESRD) Drug Market Size (US$), By Country, 2018 – 2028 
               7.4.1.1. China
               7.4.1.2. Japan
               7.4.1.3. India
               7.4.1.4. Rest of Asia Pacific
          7.4.2. Asia Pacific End Stage Renal Disease (ESRD) Drug Market Size (US$), By Product Type, 2018 – 2028
          7.4.3. Asia Pacific End Stage Renal Disease (ESRD) Drug Market Size (US$), By Distribution Channel, 2018 – 2028
          7.4.4. Asia Pacific End Stage Renal Disease (ESRD) Drug Market Size (US$), By End-use, 2018 – 2028
     7.5. Latin America End Stage Renal Disease (ESRD) Drug Market Analysis, 2018 – 2028 
          7.5.1.  Latin America End Stage Renal Disease (ESRD) Drug Market Size (US$), By Country, 2018 – 2028 
               7.5.1.1. Brazil
               7.5.1.2. Mexico
               7.5.1.3. Rest of Latin America
          7.5.2. Latin America End Stage Renal Disease (ESRD) Drug Market Size (US$), By Product Type, 2018 – 2028
          7.5.3. Latin America End Stage Renal Disease (ESRD) Drug Market Size (US$), By Distribution Channel, 2018 – 2028
          7.5.4. Latin America End Stage Renal Disease (ESRD) Drug Market Size (US$), By End-use, 2018 – 2028
     7.6. Middle East & Africa (MEA) End Stage Renal Disease (ESRD) Drug Market Analysis, 2018 – 2028 
          7.6.1.  MEA End Stage Renal Disease (ESRD) Drug Market Size (US$), By Region, 2018 – 2028 
               7.6.1.1. GCC Countries
               7.6.1.2. South Africa
               7.6.1.3. Rest of MEA
          7.6.2. MEA End Stage Renal Disease (ESRD) Drug Market Size (US$), By Product Type, 2018 – 2028
          7.6.3. MEA End Stage Renal Disease (ESRD) Drug Market Size (US$), By Distribution Channel, 2018 – 2028
          7.6.4. MEA End Stage Renal Disease (ESRD) Drug Market Size (US$), By End-use, 2018 – 2028

8. Company Profiles
     8.1. Competitive Analysis 
     8.2. Market Positioning of Key Vendors 
     8.3. Key Strategies adopted by the Leading Players
     8.4. Key End Stage Renal Disease (ESRD) Drug Providers
        8.4.1 AbbVie Inc.
                8.4.1.1 Business Description
                8.4.1.2 AbbVie Inc. Geographic Operations
                8.4.1.3 AbbVie Inc. Financial Information
                8.4.1.4 AbbVie Inc. Product Positions/Portfolio
                8.4.1.5 AbbVie Inc. Key Developments
        8.4.2 Amgen
                8.4.2.1 Business Description
                8.4.2.2 Amgen Geographic Operations
                8.4.2.3 Amgen Financial Information
                8.4.2.4 Amgen Product Positions/Portfolio
                8.4.2.5 Amgen Key Developments
        8.4.3 AstraZeneca
                8.4.3.1 Business Description
                8.4.3.2 AstraZeneca Geographic Operations
                8.4.3.3 AstraZeneca Financial Information
                8.4.3.4 AstraZeneca Product Positions/Portfolio
                8.4.3.5 AstraZeneca Key Developments
        8.4.4 Sanofi
                8.4.4.1 Business Description
                8.4.4.2 Sanofi Geographic Operations
                8.4.4.3 Sanofi Financial Information
                8.4.4.4 Sanofi Product Positions/Portfolio
                8.4.4.5 Sanofi Key Developments
        8.4.5 Kyowa Kirin Co., Ltd.
                8.4.5.1 Business Description
                8.4.5.2 Kyowa Kirin Co., Ltd. Geographic Operations
                8.4.5.3 Kyowa Kirin Co., Ltd. Financial Information
                8.4.5.4 Kyowa Kirin Co., Ltd. Product Positions/Portfolio
                8.4.5.5 Kyowa Kirin Co., Ltd. Key Developments
        8.4.6 Takeda Pharmaceutical Company Limited
                8.4.6.1 Business Description
                8.4.6.2 Takeda Pharmaceutical Company Limited Geographic Operations
                8.4.6.3 Takeda Pharmaceutical Company Limited Financial Information
                8.4.6.4 Takeda Pharmaceutical Company Limited Product Positions/Portfolio
                8.4.6.5 Takeda Pharmaceutical Company Limited Key Developments
        8.4.7 Astellas Pharma Inc.
                8.4.7.1 Business Description
                8.4.7.2 Astellas Pharma Inc. Geographic Operations
                8.4.7.3 Astellas Pharma Inc. Financial Information
                8.4.7.4 Astellas Pharma Inc. Product Positions/Portfolio
                8.4.7.5 Astellas Pharma Inc. Key Developments
        8.4.8 Bayer AG
                8.4.8.1 Business Description
                8.4.8.2 Bayer AG Geographic Operations
                8.4.8.3 Bayer AG Financial Information
                8.4.8.4 Bayer AG Product Positions/Portfolio
                8.4.8.5 Bayer AG Key Developments
        8.4.9 Vifor Pharma Management Ltd.
                8.4.9.1 Business Description
                8.4.9.2 Vifor Pharma Management Ltd. Geographic Operations
                8.4.9.3 Vifor Pharma Management Ltd. Financial Information
                8.4.9.4 Vifor Pharma Management Ltd. Product Positions/Portfolio
                8.4.9.5 Vifor Pharma Management Ltd. Key Developments
        8.4.10 Akebia Drugs, Inc.
                8.4.10.1 Business Description
                8.4.10.2 Akebia Drugs, Inc. Geographic Operations
                8.4.10.3 Akebia Drugs, Inc. Financial Information
                8.4.10.4 Akebia Drugs, Inc. Product Positions/Portfolio
                8.4.10.5 Akebia Drugs, Inc. Key Developments

LIST OF TABLES

TABLE 1 Market Snapshot: Global End Stage Renal Disease (ESRD) Drug Market 
TABLE 2 Impact Indicators 
TABLE 3 Impact Analysis of Drivers and Restraints 
TABLE 4 North America End Stage Renal Disease (ESRD) Drug Market Revenue, By Product Type, 2018 – 2028 (US$ Mn) 
TABLE 5 North America End Stage Renal Disease (ESRD) Drug Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 6 North America End Stage Renal Disease (ESRD) Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 7 Europe End Stage Renal Disease (ESRD) Drug Market Revenue, By Product Type, 2018 – 2028 (US$ Mn) 
TABLE 8 Europe End Stage Renal Disease (ESRD) Drug Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 9 Europe End Stage Renal Disease (ESRD) Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 10 Asia Pacific End Stage Renal Disease (ESRD) Drug Market Revenue, By Product Type, 2018 – 2028 (US$ Mn) 
TABLE 11 Asia Pacific End Stage Renal Disease (ESRD) Drug Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 12 Asia Pacific End Stage Renal Disease (ESRD) Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn) 
TABLE 13 Latin America End Stage Renal Disease (ESRD) Drug Market Revenue, By Product Type, 2018 – 2028 (US$ Mn) 
TABLE 14 Latin America End Stage Renal Disease (ESRD) Drug Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 15 Latin America End Stage Renal Disease (ESRD) Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)
TABLE 16 MEA End Stage Renal Disease (ESRD) Drug Market Revenue, By Product Type, 2018 – 2028 (US$ Mn) 
TABLE 17 MEA End Stage Renal Disease (ESRD) Drug Market Revenue, By Distribution Channel, 2018 – 2028 (US$ Mn) 
TABLE 18 MEA End Stage Renal Disease (ESRD) Drug Market Revenue, By End-use, 2018 – 2028 (US$ Mn)

LIST OF FIGURES

FIG. 1 Global End Stage Renal Disease (ESRD) Drug: Market Segmentation 
FIG. 2 Global End Stage Renal Disease (ESRD) Drug Market: Research Methodology 
FIG. 3 Top-Down and Bottom-up Approach 
FIG. 4 Global End Stage Renal Disease (ESRD) Drug Market, By Product Type, 2019 (US$ Mn) 
FIG. 5 Global End Stage Renal Disease (ESRD) Drug Market, By Distribution Channel, 2019 (US$ Mn) 
FIG. 6 Global End Stage Renal Disease (ESRD) Drug Market, By End-use, 2019 (US$ Mn) 
FIG. 7 Global End Stage Renal Disease (ESRD) Drug Market, By Geography, 2019 (US$ Mn) 
FIG. 8 Global End Stage Renal Disease (ESRD) Drug Market Revenue and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG. 9 Attractive Investment Proposition 
FIG. 10 Market Positioning of Key End Stage Renal Disease (ESRD) Drug Providers, 2019
FIG. 11 Global End Stage Renal Disease (ESRD) Drug Market Revenue Contribution, By Product Type, 2019 & 2028 (Value %) 
FIG. 12 Global End Stage Renal Disease (ESRD) Drug Market Revenue Contribution, By Distribution Channel, 2019 & 2028 (Value %) 
FIG. 13 Global End Stage Renal Disease (ESRD) Drug Market Revenue Contribution, By End-use, 2019 & 2028 (Value %) 
FIG. 14 North America End Stage Renal Disease (ESRD) Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 15 Europe End Stage Renal Disease (ESRD) Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 16 Asia Pacific End Stage Renal Disease (ESRD) Drug Market Revenue, 2018 – 2028, (US$ Mn) 
FIG. 17 Latin America End Stage Renal Disease (ESRD) Drug Market Revenue, 2018 – 2028, (US$ Mn)
FIG. 18 MEA End Stage Renal Disease (ESRD) Drug Market Revenue, 2018 – 2028, (US$ Mn)

Key Takeaways:

1. Market value and estimate of the End Stage Renal Disease (ESRD) Drug market for the period from 2020 to 2028
2. Compounded annual growth rate (CAGR%) for individual segments in various regional markets for a period from 2020 to 2028
3. Value chain analysis
4. Market share study combined with competitive landscape of major players
5. Profiles of major market players covering overall business operations, geographic occurrence, product portfolio, financial status and news coverage 

List of Tables

TABLE  Market Snapshot: Global End Stage Renal Disease (ESRD) Drug Market
TABLE  Impact Pointers
TABLE  Impact Analysis of Drivers and Restraints
TABLE  North America End Stage Renal Disease (ESRD) Drug Market Value, By Segment1, 2018 – 2028
TABLE  North America End Stage Renal Disease (ESRD) Drug Market Value, By Segment2, 2018 – 2028
TABLE  North America End Stage Renal Disease (ESRD) Drug Market Value, By Country, 2018 – 2028
TABLE  Europe End Stage Renal Disease (ESRD) Drug Market Value, By Segment1, 2018 – 2028
TABLE  Europe End Stage Renal Disease (ESRD) Drug Market Value, By Segment2, 2018 – 2028
TABLE  Europe End Stage Renal Disease (ESRD) Drug Market Value, By Country, 2018 – 2028
TABLE  Asia Pacific End Stage Renal Disease (ESRD) Drug Market Value, By Segment1, 2018 – 2028
TABLE  Asia Pacific End Stage Renal Disease (ESRD) Drug Market Value, By Segment2, 2018 – 2028
TABLE  Asia Pacific End Stage Renal Disease (ESRD) Drug Market Value, By Country, 2018 – 2028
TABLE  Latin America End Stage Renal Disease (ESRD) Drug Market Value, By Segment1, 2018 – 2028
TABLE  Latin America End Stage Renal Disease (ESRD) Drug Market Value, By Segment2, 2018 – 2028
TABLE  Latin America End Stage Renal Disease (ESRD) Drug Market Value, By Country, 2018 – 2028
TABLE  MEA End Stage Renal Disease (ESRD) Drug Market Value, By Segment1, 2018 – 2028
TABLE  MEA End Stage Renal Disease (ESRD) Drug Market Value, By Segment2, 2018 – 2028
TABLE  MEA End Stage Renal Disease (ESRD) Drug Market Value, By Country, 2018 – 2028
TABLE  AbbVie Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Amgen: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  AstraZeneca: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Sanofi: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Kyowa Kirin Co., Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Takeda Pharmaceutical Company Limited: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Astellas Pharma Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Bayer AG: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Vifor Pharma Management Ltd.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
TABLE  Akebia Drugs, Inc.: Company Snapshot (Company Details, Geographical Presence, Product Portfolio, Recent News and Announcements)
 

List of Figures

FIG.  Global End Stage Renal Disease (ESRD) Drug Market: Research Methodology
FIG.  Top-Down and Bottom Up Approach
FIG.  Global End Stage Renal Disease (ESRD) Drug Market, By Segment1, 2019 (US$ Mn)
FIG.  Global End Stage Renal Disease (ESRD) Drug Market, By Segment2, 2019 (US$ Mn)
FIG.  Global End Stage Renal Disease (ESRD) Drug Market, By Geography, 2019 (US$ Mn)
FIG.  Global End Stage Renal Disease (ESRD) Drug Market Value and Growth, 2018 – 2028, (US$ Mn) (Y-o-Y %)
FIG.  Attractive Investment Proposition
FIG.  Market Positioning of Key End Stage Renal Disease (ESRD) Drug Providers, 2016
FIG.  Global End Stage Renal Disease (ESRD) Drug Market Value Share, By Segment1, 2019 & 2028 (% Value)
FIG.  Global Vitamin D Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Sterols Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Potassium Binders Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Calcium-Based Phosphate Binders Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Others Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global End Stage Renal Disease (ESRD) Drug Market Value Share, By Segment2, 2019 & 2028 (% Value)
FIG.  Global Online Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Retail Pharmacies Market Value, 2018 – 2028, (US$ Mn)
FIG.  Global Market Value, 2018 – 2028, (US$ Mn)
FIG.  U.S. End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Canada End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  UK End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Germany End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  France End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Europe End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  China End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Japan End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  India End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Asia Pacific End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Mexico End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Brazil End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of Latin America End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  GCC Countries End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  South Africa End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)
FIG.  Rest of MEA End Stage Renal Disease (ESRD) Drug Market Value, 2018 – 2028, (US$ Mn)